Has Whitney Fancher, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,650 in general payments to Whitney Fancher, MD across 171 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Whitney Fancher, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Whitney Fancher, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Whitney Fancher, MD

MOHS-Micrographic Surgery · Longview, WANPI 1053699645

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations.

$3,650in general payments, 2019–2025

Across 171 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$666
Novartis$365
E.r. Squibb & Sons, L.L.C.$356
Kerecis Limited$292
Lilly USA, LLC$167
Sensus Healthcare, Inc.$165
plus $2K from 26 others

What the payments were for

Food & beverage$3,650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	34	$666
Novartis	23	$365
E.r. Squibb & Sons, L.L.C.	11	$356
Kerecis Limited	9	$292
Lilly USA, LLC	9	$167
Sensus Healthcare, Inc.	1	$165
UCB, Inc.	9	$162
Johnson & Johnson(2 entities)	12	$158
Organogenesis Inc.	6	$143
Sun Pharmaceutical Industries Inc.	7	$139
Convatec Inc.	4	$126
Regeneron Healthcare Solutions, Inc.	5	$83
Janssen Scientific Affairs, LLC	1	$77
Agiliti Health, Inc.	2	$72
Organon	7	$72
Incyte Corporation	3	$69
Pfizer	3	$63
Smith+Nephew	2	$61
Galderma Laboratories, L.p.	3	$60
LEO Pharma Inc.	3	$49
Amgen	2	$42
Surgenex LLC	2	$41
Mayne Pharma Commercial LLC	2	$33
Sanofi	2	$32
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$27
Journey Medical Corporation	1	$22
VYNE Pharmaceuticals Inc.	1	$21
Helsinn Therapeutics (U.S.), Inc.	1	$18
Arcutis Biotherapeutics, Inc.	1	$17
Dermavant Sciences, Inc.	1	$17
Verrica Pharmaceuticals Inc.	1	$17
Strata Skin Sciences, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,650 in reported general payments places this provider in the 70th percentile of 38 mohs-micrographic surgery providers in Washington.

See all mohs-micrographic surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$1,130,887

Medicare patients

362

Services billed

3,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mupirocin	96	$703
Cephalexin	89	$702
Doxycycline Hyclate	34	$274
Gentamicin Sulfate	13	$241
Levofloxacin	16	$67
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	20	$44

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Longview

Ein Gun SongMill Creek$4.5M
Jeremy PeckRichland$9K
Marcus TanRenton$8K
Mikel MuseVancouver$6K
Jennifer ReichelSeattle$5K
Kirk EcklundYakima$5K
John NiaSpokane$5K
Mustufa JafryMill Creek$4K
Maureen MooneyUniversity Place$4K
Nobuyoshi KageyamaRenton$4K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →